- Electronics, IT and Telecomms
- Industrial manufacturing, Material and Transport Technologies
- Industrial Technologies
- Energy Technology
- Physical Sciences and Exact Sciences
- Biological Sciences
- Agriculture and Marine Resources
- Agrofood Industry
- Measurements and Standards
- Protecting Man and Environment
- Social and Economics concerns
- Communications
- Computer related
- Electronics Related Market
- Genetic Engineering / Molecular Biology
- Medical Health related
- Energy Market
- Consumer related
- Industrial Products
- Other
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this:
5-MER Peptide to Ameliorate Coronavirus-Induced Inflammation of the Upper Respiratory Tract and Lungs5-MER Peptide to Ameliorate Coronavirus-Induced Inflammation of the Upper Respiratory Tract and Lungs This study will test the hypothesis that treatment with a peptide comprising five units (5-MER), which is administered by injection or oral delivery, will substantially reduce chronic inflammation of the upper respiratory tract and lungs, thus ameliorating the effects of the Coronavirus disease. This will be achieved by targeting a major pro-inflammatory protein called SAA which plays an active role in the development of the disease. Furthermore, it is anticipated that the 5-MER peptide may also activate genes that provide resistance to chronic inflammation mediated by Coronavirus. Project ID : 47-2020-10890
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this:
High-Throughput Sequencing Methods to Test SamplesHighly parallel test for the presence of SARS-CoV-2 The currently used test for SARS-CoV2 virus uses molecular methods for detecting the presence of viral RNA sequences in subject samples. This is the approved gold standard in the field. The current application of this test requires several cumbersome steps that are labor intensive and require non-trivial reagents (which are becoming a global bottleneck). It is clear that during the next stage of managing the COVID19 pandemic, large scale testing will be needed. Project ID : 47-2020-10893
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this:
Novel Activating Antibodies for Viral TreatmentNovel Activating Antibodies for Viral Treatment Various pathogens (bacteria and viruses as well) bind to specific cell adhesion molecule in order to inhibit the immune response and/or to infect the host cells. However,upon binding and induction/activation, the cell adhesion molecule suppresses virus production by an SHP2-dependent process which involves also suppression of mTOR-mediated protein biosynthesis. Project ID : 47-2020-10898
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this:
Rapid Computational Screening of Natural Products for COVID-19 Anti-Viral AgentsSome edible compounds are potent antiviral agents and were tested successfully against SARS and MERS viruses. They hence provide an large source for rapid development and production of cure against COVID-19. These compounds are commercially available, and are generally recognized as safe (GRAS), with a vast chemical diversity. Despite the high-level genetic similarity to other coronaviruses, such as SARS-CoV and MERS-CoV, recent works demonstrate major structural differences in SARS-CoV2 (the causal agent of COVID-19 disease) proteins. The need for specific anti-SARS-COV2 treatments is acute. Rapid screening of the food derived compounds, using chemoinformatic modeling tools that are common in our lab, allow the identification of a small number of potent antiviral candidate inhibitors of recent published SARS-CoV2 target proteins. Project ID : 47-2020-10884
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this:
Plant-based Diagnostic Kit to Detect Sick and Recovered SARS-CoV-2 Virus PatientsGenetically modified plant systems that allow identification of SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies Applications Preventing the spread of the epidemic Restoring economic activity by returning immune-positive, symptomless people to work Features System can be rapidly reproduced through seeds Essentially unlimited quantities, extremely inexpensive Can be used in any environment No need for special machinery Adaptable to other diseases Project ID : 47-2020-10883
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this:
Using Peptide Nucleic Acids (PNAs) as a Tool to Diagnose COVID-19Using Peptide Nucleic Acids (PNAs) as a Tool to Diagnose COVID-19 We offer a fast and efficient diagnostic method which can be applied to a large amount of tests in a short time. Our method is based on a kit which identifies specifically the viral RNA biomarker. The test is characterized by reliability, sensitivity, rapid (not more than 10-15 minutes), low toxicity and reasonable cost. Project ID : 47-2020-10881
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this:
Systematic Computational Drug Repositioning to Treat COVID-19Systematic Computational Drug Repositioning to Treat COVID-19 The genetic revolution which has taken place in recent years brings new opportunities to the field of drug discovery & repositioning. Using advanced comparative genomic, and data integration, our lab has been developing a state-of-the-art AI algorithm which maps drug and food supplements that are useful in treating diseases and improving health conditions. To create this algorithm, we have been integrating and analyzing massive amounts of genomic data from 1,600 genomes, 14 thousand compounds, 20,000 human genes, and a comprehensive database of phenotypic data. Project ID : 47-2020-10880
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this:
Screening of Drugs to Inhibit Viral InfectionsOur group has published a lot of work on the SARS Coronavirus. We were the first to characterize an important protein in the virus that has a very unusual structure and sequence (E protein). Moreover, this protein was unique to SARS and was not found in any other Coronavirus. Now importantly, the new 2019 Coronavirus has a very similar protein! Project ID : 47-2020-10879
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this:
Deciphering the Virus-Host Tango: Understanding network of interactions through evolution, structure, dynamics, and computational designDeciphering the Virus-Host Tango: Understanding network of interactions through evolution, structure, dynamics, and computational designProject ID : 47-2020-10875
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this:
Using Signature Genes to Detect Early-Stage Coronavirus and Predict Individual OutcomesUsing Signature Genes to Detect Early-Stage Coronavirus and Predict Individual Outcomes Project ID : 47-2020-10876 Test signature genes of host for non-invasive and early detection of Coronavirus infection, even before the infected person is symptomatic (also allowing differentiation from influenza virus infections). Moreover, this unique signature can be used to predict disease outcome in infected individuals as well as predict the vulnerability to the virus in non- infected individuals. The last can be valuable for screening of vulnerable populations such as medical teams and caregivers.
Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
Interactive Self-Guided Tours on the History of Urban MedicineContent for tours in history of medicine Project ID : 45-2020-10831 Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
Pepper Genome Editing-Cas9 Stable TransformationAlexander (Sasha) Vainstein - Pepper Genome Editing-Cas9 Stable Transformation (TTM# 13921) - The researcher has developed a protocol for successfully transforming sweet and hot pepper varieties to stably express the Cas9 endonuclease of the CRISPR gene editing tool. To date, no other research group has described Cas9 gene edited pepper plants. The researcher’s Cas9-pepper lines were used for genome editing via virus-driven trans-acting guides–for all the chosen target genes/traits. This innovation will allow breeders to enhance their exhisiting pepper varieties with novel traits. Furthermore, after back-crossing the lines the breeder will be able to remove the Cas9 gene leaving behind only the gene-edited pepper varieties. These resulting lines may be considered Non-GMO in certain geographies. By combining this technology with the MemoGene TTM#1705, the breeder/researcher may screen many phenotypes when transforming a plethora of guide RNAs. IP Position: Know-How Yissum Online: http://www.yissum.co.il/technologies/project/13921 Project ID : 47-2020-13921
Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
High Throughput Screening of Antimicrobial Agents Using MicrofluidicsYonatan is a Phytopathology expert using microfluidics system to do high throughput screening of libraries to identify antimicrobial agents which can be either chemical or biological (proteins or bacteria). Yonatan is testing pathogens sensitivity against combinations of bacteria and chemical agents from the libraries using the high-throughput microfluidics system. When Potential Producer, Potential Inducer have a combined affect on a Pathogen target (killing) efficiency become of interest. This is because in nature a single bacteria species is susceptible to environmental stresses but when combined with helper bacteria they support each other synergistically. Project ID : 47-2019-10825